Preparation, Characterization and in vivo Study of Borneol-Baicalin-Liposomes for Treatment of Cerebral Ischemia-Reperfusion Injury
DOI: https://doi.org/10.2147/IJN.S259938
IF: 7.033
2020-08-12
International Journal of Nanomedicine
Abstract:Yulu Zhang, 1, * Songyu Liu, 1, * Jinyan Wan, 1, * Qiyue Yang, 2 Yan Xiang, 1 Li Ni, 1 Yu Long, 1 Mingquan Cui, 1 Zhimin Ci, 1 Donglei Tang, 1 Nan Li 1 1 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People's Republic of China; 2 Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China *These authors contributed equally to this work Correspondence: Nan Li College of Pharmacy, Chengdu University of Traditional Chinese Medicine, No. 1166, Liutai Avenue, Chengdu 611137, People's Republic of China Tel +86-28-61801001 Email 55743198@qq.com Purpose: Baicalin (BA) has a good neuroprotective effect, but it is eliminated quickly in the body and does not easily reach the brain. In this experiment, borneol (BO) was used as an auxiliary drug to prepare borneol-baicalin-liposomes (BO-BA-LP) to prolong the efficacy time of BA, synergistically synergize, introduce drugs into the brain, and better exert the therapeutic effect on cerebral ischemia-reperfusion (I/R) injury. Methods: Through single-factor inspection and response surface optimization analysis, obtained the best preparation process of BO-BA-LP and characterized by various analytical techniques. Validated the long-term effectiveness of BA-BO-LP through pharmacokinetic studies and conducted pharmacodynamic studies on the middle cerebral artery occlusion (MCAO) rat model to verify the therapeutic effect of BO-BA-LP on cerebral I/R injury. Results: The optimum preparation conditions of BO-BA-LP were as follows: the dosage of BO was 9.55 mg, the ratio of phospholipid to drug was 4.02:1, the ratio of phospholipid to cholesterol was 7.25:1, the entrapment efficiency (EE) was 41.49%, and the drug loading (DL) was 4.29%. The particle size range of the liposomes was 167.1 nm, and the polydispersity index (PDI) range was 0.113. The results of pharmacokinetic experiments showed that the combination of BA and BO liposomes effectively improved the pharmacokinetic parameters of BA and prolonged the half-life of BA. Pharmacodynamic studies have found that, compared with BA-LP, BO-BA-LP can significantly improve neurological deficits, cerebral infarction volume, and brain pathological states on MCAO rats. Conclusion: These results demonstrated that BO-BA-LP can improve the circulation of drugs in the blood, and the addition of BO can enhance the therapeutic effect of BA and effectively improve cerebral I/R. Keywords: borneol-baicalin-liposome, pharmacokinetics, pharmacodynamics, MCAO
pharmacology & pharmacy,nanoscience & nanotechnology